IN2014CN00817A - - Google Patents

Info

Publication number
IN2014CN00817A
IN2014CN00817A IN817CHN2014A IN2014CN00817A IN 2014CN00817 A IN2014CN00817 A IN 2014CN00817A IN 817CHN2014 A IN817CHN2014 A IN 817CHN2014A IN 2014CN00817 A IN2014CN00817 A IN 2014CN00817A
Authority
IN
India
Prior art keywords
isoquinolin
yloxy
piperidin
preparation
relates
Prior art date
Application number
Inventor
Norbert Nagel
Bruno Baumgartner
Harald Berchtold
Oliver Plettenburg
Dieter Kadereit
Mandy Mohnicke
Simon Gessler
Joachim Tillner
Original Assignee
Sanofi Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Sa filed Critical Sanofi Sa
Publication of IN2014CN00817A publication Critical patent/IN2014CN00817A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/06—Antiabortive agents; Labour repressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Abstract

The present invention relates to crystalline solvates of 6 (Piperidin 4 yloxy) 2H isoquinolin 1 one hydrochloride processes for their preparation and the use thereof.
IN817CHN2014 2011-07-08 2012-06-27 IN2014CN00817A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP11305890 2011-07-08
EP11306033 2011-12-29
PCT/EP2012/062431 WO2013007518A1 (en) 2011-07-08 2012-06-27 Crystalline solvates of 6-(piperidin-4-yloxy)-2h-isoquinolin-1-one hydrochloride

Publications (1)

Publication Number Publication Date
IN2014CN00817A true IN2014CN00817A (en) 2015-04-03

Family

ID=46397257

Family Applications (1)

Application Number Title Priority Date Filing Date
IN817CHN2014 IN2014CN00817A (en) 2011-07-08 2012-06-27

Country Status (22)

Country Link
US (2) US8710078B2 (en)
EP (1) EP2729460B1 (en)
JP (1) JP6357100B2 (en)
KR (1) KR102013566B1 (en)
CN (1) CN103781778B (en)
AU (1) AU2012283276B2 (en)
CA (1) CA2843773C (en)
CO (1) CO6870040A2 (en)
CY (1) CY1118326T1 (en)
DK (1) DK2729460T3 (en)
ES (1) ES2568245T3 (en)
HK (1) HK1192546A1 (en)
HR (1) HRP20160356T1 (en)
HU (1) HUE027309T2 (en)
IN (1) IN2014CN00817A (en)
MA (1) MA35340B1 (en)
PL (1) PL2729460T3 (en)
RU (1) RU2619129C2 (en)
SG (1) SG2014007520A (en)
SI (1) SI2729460T1 (en)
WO (1) WO2013007518A1 (en)
ZA (1) ZA201400941B (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE027309T2 (en) * 2011-07-08 2016-10-28 Sanofi Sa Crystalline solvates of 6-(piperidin-4-yloxy)-2h-isoquinolin-1-one hydrochloride

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2396079A1 (en) * 2000-01-07 2001-07-19 Transform Pharmaceuticals, Inc. High-throughput formation, identification, and analysis of diverse solid-forms
UA93882C2 (en) 2005-07-26 2011-03-25 Санофи-Авентис Piperidinyl-substituted isoquinolone derivatives as rho-kinase inhibitors
TW200738682A (en) 2005-12-08 2007-10-16 Organon Nv Isoquinoline derivatives
US7478743B2 (en) 2006-02-28 2009-01-20 Holley Jr John M Carton for tapered and cylindrical articles
EP2102187B1 (en) 2006-12-27 2015-04-01 Sanofi Substituted isoquinoline and isoquinolinone derivatives as inhibitors of rho-kinase
EP2132194B1 (en) * 2006-12-27 2011-03-16 Sanofi-Aventis Substituted isoquinolines and their use as rho-kinase inhibitors
EP2240441B1 (en) * 2007-12-26 2015-06-03 Sanofi Process for the preparation of 6-substituted-1-(2h)-isoquinolinones
HUE027309T2 (en) * 2011-07-08 2016-10-28 Sanofi Sa Crystalline solvates of 6-(piperidin-4-yloxy)-2h-isoquinolin-1-one hydrochloride

Also Published As

Publication number Publication date
PL2729460T3 (en) 2016-07-29
AU2012283276B2 (en) 2014-07-24
US8710078B2 (en) 2014-04-29
RU2014104358A (en) 2015-08-20
CA2843773A1 (en) 2013-01-17
CA2843773C (en) 2018-11-06
HK1192546A1 (en) 2014-08-22
EP2729460A1 (en) 2014-05-14
JP6357100B2 (en) 2018-07-11
US20130012444A1 (en) 2013-01-10
ZA201400941B (en) 2015-05-27
MA35340B1 (en) 2014-08-01
EP2729460B1 (en) 2016-01-13
CN103781778B (en) 2015-10-07
JP2014518235A (en) 2014-07-28
CO6870040A2 (en) 2014-02-20
HUE027309T2 (en) 2016-10-28
NZ620864A (en) 2015-08-28
RU2619129C2 (en) 2017-05-12
AU2012283276A1 (en) 2014-02-27
CN103781778A (en) 2014-05-07
CY1118326T1 (en) 2017-06-28
WO2013007518A1 (en) 2013-01-17
KR20140045550A (en) 2014-04-16
KR102013566B1 (en) 2019-08-23
HRP20160356T1 (en) 2016-05-06
SG2014007520A (en) 2014-07-30
SI2729460T1 (en) 2016-05-31
DK2729460T3 (en) 2016-04-18
US20140221656A1 (en) 2014-08-07
ES2568245T3 (en) 2016-04-28

Similar Documents

Publication Publication Date Title
GEP201706745B (en) Forms of rifaximin and usage thereof
IN2015DN01156A (en)
TN2011000673A1 (en) Bace inhibitors
MY181898A (en) Heterocyclic compounds and uses thereof
MX355728B (en) Kinase inhibitors.
MX2013008390A (en) Preparation of metal-triazolate frameworks.
UA111186C2 (en) Methods and compositions for preparing noribogaine from voacangine
JO2887B1 (en) Spiropiperidine compounds as orl-1 receptor antagonists‎
IN2014DN10670A (en)
MY167208A (en) Partially Hydrolyzed Casein-Whey Nutritional Compositions for Reducing the Onset of Allergies
HK1202867A1 (en) Substituted anilines as ccr(4) antagonists ccr(4)
IN2014CN03854A (en)
IL221471A0 (en) Process for the preparation of alpha form of imatinib mesylate
IN2013MN02414A (en)
GEP201706626B (en) Synthesis of (s)-nifuratel
MY166314A (en) Alpha1-proteinase inhibitor for delaying the onset or progression of pulmonary exacerbations
MX351631B (en) Compositions and methods for reducing the incidence of equine digestive disorders.
IN2012DN01292A (en)
GB201107985D0 (en) Process
PL2552925T3 (en) Process for the preparation of silicon containing azodicarbamides
MX347541B (en) Sialic acid analogs.
IN2012DN01929A (en)
MY160625A (en) Process for preparing pan-cdk inhibitors of the formula(i), and intermediates in the preparation
IN2014DN09451A (en)
MX2013009386A (en) New azaspirodecanone compounds.